CA2446705A1 - Compositions d'agents therapeutiques a base de quinoxaline et d'acides gras ayant des caracteristiques pharmacocinetiques ameliorees - Google Patents

Compositions d'agents therapeutiques a base de quinoxaline et d'acides gras ayant des caracteristiques pharmacocinetiques ameliorees Download PDF

Info

Publication number
CA2446705A1
CA2446705A1 CA002446705A CA2446705A CA2446705A1 CA 2446705 A1 CA2446705 A1 CA 2446705A1 CA 002446705 A CA002446705 A CA 002446705A CA 2446705 A CA2446705 A CA 2446705A CA 2446705 A1 CA2446705 A1 CA 2446705A1
Authority
CA
Canada
Prior art keywords
component
composition
efficacy enhancing
therapeutic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002446705A
Other languages
English (en)
Other versions
CA2446705C (fr
Inventor
David F. Woodward
Gyorgy Ambrus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/847,935 external-priority patent/US20020198209A1/en
Application filed by Individual filed Critical Individual
Publication of CA2446705A1 publication Critical patent/CA2446705A1/fr
Application granted granted Critical
Publication of CA2446705C publication Critical patent/CA2446705C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention porte sur des composants renfermant un composant thérapeutique et un composant d'amélioration de l'efficacité permettant d'améliorer la disposition pharmacocinétique du composant thérapeutique. Ce dernier peut contenir un agoniste .alpha.-2-adrénergique, alors que le composant d'amélioration de l'efficacité peut contenir des acides gras. Selon un mode de réalisation, le composant thérapeutique et le composant d'amélioration de l'efficacité forment un complexe.
CA2446705A 2001-05-03 2002-05-03 Compositions d'agents therapeutiques a base de quinoxaline et d'acides gras ayant des caracteristiques pharmacocinetiques ameliorees Expired - Fee Related CA2446705C (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/847,935 2001-05-03
US09/847,935 US20020198209A1 (en) 2001-05-03 2001-05-03 Compositions having enhanced pharmacokinetic characteristics
US10/136,240 2002-05-01
US10/136,240 US7491383B2 (en) 2001-05-03 2002-05-01 Compositions having enhanced pharmacokinetic characteristics
PCT/US2002/014241 WO2002089853A2 (fr) 2001-05-03 2002-05-03 Compositions ayant des caracteristiques pharmacocinetiques ameliorees

Publications (2)

Publication Number Publication Date
CA2446705A1 true CA2446705A1 (fr) 2002-11-14
CA2446705C CA2446705C (fr) 2012-03-06

Family

ID=26834149

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2446705A Expired - Fee Related CA2446705C (fr) 2001-05-03 2002-05-03 Compositions d'agents therapeutiques a base de quinoxaline et d'acides gras ayant des caracteristiques pharmacocinetiques ameliorees

Country Status (5)

Country Link
EP (1) EP1390073A2 (fr)
JP (1) JP2004528369A (fr)
AU (1) AU2002256471B2 (fr)
CA (1) CA2446705C (fr)
WO (1) WO2002089853A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144399A1 (fr) * 2007-05-18 2008-11-27 Bausch & Lomb Incorporated Complexes comprenant des agonistes du récepteur α2-adrénergique et compositions associées
US8394800B2 (en) 2009-11-19 2013-03-12 Galderma Laboratories, L.P. Method for treating psoriasis
SG11202100985QA (en) * 2018-08-29 2021-03-30 Cellix Bio Private Ltd Ophthalmic compositions and methods for the treatment of eye disorders and skin diseases
EP4295837A1 (fr) * 2022-06-21 2023-12-27 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Composition ophtalmique comprenant de la brimonidine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188393A (en) * 1977-04-22 1980-02-12 Sandoz Ltd. Treating spastic conditions or relaxing muscles
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US4908389A (en) * 1986-08-27 1990-03-13 Warner-Lambert Company Penetration enhancement system
DE3729299A1 (de) * 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
US5994392A (en) * 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
JPH085779B2 (ja) * 1989-09-22 1996-01-24 杏林製薬株式会社 フレロキサシン点眼液
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure
JPH082801B2 (ja) * 1989-11-09 1996-01-17 株式会社資生堂 経皮吸収促進剤及び皮膚外用剤
CA2031469A1 (fr) * 1989-12-28 1991-06-29 Larry A. Wheeler Utilisation de composes d'inclusion de prostaglandines avec des cyclodextrines dans le traitement de l'hypertension oculaire
EP0664707B1 (fr) * 1992-10-13 1997-06-04 Alcon Laboratories, Inc. Combinaisons de prostaglandines et de derives de clonidine pour le traitement du glaucome
JP4024852B2 (ja) * 1994-11-17 2007-12-19 東レ株式会社 「経皮吸収製剤」
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
IL127956A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Inclusion complex containing indole selective serotonin agonist
JP3607062B2 (ja) * 1997-10-24 2005-01-05 株式会社コーセー 脂肪蓄積抑制剤及びそれを含有する皮膚外用剤
MY116782A (en) * 1997-12-22 2004-03-31 Otsuka Pharma Co Ltd Water-soluble eye drop
CA2337349A1 (fr) * 1998-07-21 2000-02-03 Gerald S. Ponticello Compositions ophtalmiques destinees au traitement de l'hypertension oculaire
JP5138128B2 (ja) * 1998-08-21 2013-02-06 千寿製薬株式会社 水性液剤
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
JP2001081048A (ja) * 1999-09-10 2001-03-27 Wakamoto Pharmaceut Co Ltd 眼圧降下剤
HUP0303197A3 (en) * 2000-07-14 2008-03-28 Allergan Inc Compositions containing alpha-2 adrenergic agonist components
US20020198210A1 (en) * 2001-05-03 2002-12-26 Allergan Sales Inc. Alpha-2-adrenergic agonist/fatty acid compositions

Also Published As

Publication number Publication date
WO2002089853A2 (fr) 2002-11-14
AU2002256471B2 (en) 2007-05-24
WO2002089853A3 (fr) 2003-12-11
EP1390073A2 (fr) 2004-02-25
JP2004528369A (ja) 2004-09-16
CA2446705C (fr) 2012-03-06

Similar Documents

Publication Publication Date Title
AU2018267578B2 (en) Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
AU753462B2 (en) Preservative system for topically administrable pharmaceutical compositions containing a fatty acid/amino acid soap
KR101951511B1 (ko) 레바미피드와 누액 유지 작용을 갖는 약제를 포함하는 전안부 질환 치료제
CA2502437A1 (fr) Procede et composition contenant du latanoprost destines au traitement de l'hypertension oculaire et d'un glaucome
NZ337322A (en) Compositions containing a prostaglandin active agent useful for reducing ocular hypertension
WO2006001963A1 (fr) Compositions pharmaceutiques renfermant des cyclosporines
EP0824916B1 (fr) Gouttes oculaires de pranoprofene renfermant un amine organique
JPH0640910A (ja) ビタミンｅ点眼剤
JP4438908B2 (ja) テルペノイドエマルション
CA2282757A1 (fr) Composition ophtalmique
JP2824863B2 (ja) α▲下１▼―ブロッカー点眼剤
EP1250133A1 (fr) Compositions ophtalmiques anti-allergiques appropriees pour etres utilisees avec des lentilles de contact
EP1589971A1 (fr) Composition ophtalmique contenant de la loratadine
EP1283043B1 (fr) Composition ophtalmique
CA2446705A1 (fr) Compositions d'agents therapeutiques a base de quinoxaline et d'acides gras ayant des caracteristiques pharmacocinetiques ameliorees
WO1994028900A1 (fr) Procedes et comositions d'abaissement de la pression intra-oculaire
JP2002020279A (ja) 点眼液
JP2010006796A (ja) 非イオン性シリコーンハイドロゲルコンタクトレンズ用点眼剤
JP2002114686A (ja) 点眼剤組成物
JPH08104636A (ja) 点眼製剤
ES2197781A1 (es) Composiciones farmaceuticas liquidas de base acuosa en forma de suspension para la administracion por via oral de ibuprofeno.
AU2008273874A1 (en) Complexes of prostaglandin derivatives and monosubstituted, charged beta-cyclodextrins
JP2006089460A (ja) 眼科用粘稠化剤
CA2567418C (fr) Epaississant a usage ophthalmique
JP2005239622A (ja) 角膜障害治療剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160503